Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice

Denis R Clohisy, Patrick F. O'Keefe, Margaret L. Ramnaraine

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Recent studies indicate that the bisphosphonate pamidronate reduces skeletal complications caused by tumor osteolysis. In this investigation, the cellular mechanism through which pamidronate affects tumor-induced osteoclastogenesis is studied in osteopetrotic mice. A unique animal model is employed which studies the effect of pamidronate on a tumor (2472 sarcoma) which induces osteoclastogenesis in osteoclast-deficient mice (oplop). This model provides opportunity to specifically study effects on osteoclast formation and findings suggest that pamidronate decreases the number of osteoclasts at sites of 2472 tumor by decreasing the number of osteoclast precursor cells at the level of myeloid precursors.

Original languageEnglish (US)
Pages (from-to)554-558
Number of pages5
JournalJournal of Orthopaedic Research
Issue number4
StatePublished - 2001

Bibliographical note

Funding Information:
Work was supported by the National Institutes of Health, Institute of Arthritis and Musculoskeletal and Skin Diseases (AR43595), and the Roby C. Thompson Jr. Endowment in Musculoskeletal Oncology.


Dive into the research topics of 'Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice'. Together they form a unique fingerprint.

Cite this